In a surprising turn of events, the Advisory Committee of experts on Biogen’s experimental Alzheimer’s drug aducanumab recommended against FDA approval of the drug…
Today, the public gets a preview of FDA staff recommendations and drugmaker presentations in advance of this Friday’s advisory committee meeting to discuss Biogen’s…
In yet another encouraging step toward the development of what could be the first drug approved for Alzheimer’s disease, the Federal Drug Administration today…
In another step toward what could be the first treatment for early stage Alzheimer’s, Biogen and Eisai today said they have completed an application…
The U.S. Food and Drug Administration (FDA) has approved a re-dosing study for patients formerly enrolled in Biogen’s phase three clinical trials of its…
Last week, Biogen announced that its Alzheimer’s drug aducanumab was effective in combating Alzheimer’s disease after all, and that it would be reviving a…
Last week, Biogen announced that its Alzheimer’s drug aducanumab was effective in combating Alzheimer’s disease, and that it would be reviving a trial cancelled…